Van de site van immutep.
Following this data review, the DSMB recommended that the study advance
with enrolment for the randomised portion of the study. All six patients (age range, 50-83 years; 2 women)
received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported.
Professor Matejovic, Principal Investigator for the study, stated, “Sadly, hospitals and doctors in the Czech Republic are increasingly overwhelmed and are facing severe challenges treating the high volume of patients
with COVID-19. Despite this, the DSMB has prioritized the review of the safety data for the first six patients
in the EAT COVID Phase II study. We are pleased with their recommendation to continue the trial and move
ahead with the randomised, placebo-controlled portion of the study.”